A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Incyte Corporation
Incyte Corporation
National Institutes of Health Clinical Center (CC)
University of Nebraska
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Mayo Clinic
National Institutes of Health Clinical Center (CC)
Mayo Clinic
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
Mayo Clinic
University of Arizona
Yale University
US Oncology Research
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Mayo Clinic
H. Lee Moffitt Cancer Center and Research Institute
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center